Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease.

ABSTRACT: Biologicals and small molecules have revolutionized the medical management of inflammatory bowel diseases (IBD), yet they are only effective in a proportion of patients, and their impact on changing the natural history of the disease is still debatable. Recently, the concept of combining targeted biologics and small-molecule therapies has been introduced to the treatment of IBD. Dual-targeted therapy (sequential and combined), which is the combination of two targeted therapies, might be a reasonable choice for patients to break through the therapeutic ceiling. A recent randomized clinical trial (VEGA) provided the first controlled evidence that the short-term combination of two biological agents may lead to superior disease control than either of the agents alone in patients with ulcerativ

SUBMITTER: Wetwittayakhlang P 

PROVIDER: S-EPMC10836999 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature